Home > Publications database > Suitability of superficial electron paramagnetic resonance dosimetry for in vivo measurement and verification of cumulative total doses during IMRT: A proof of principle. > print

001     169693
005     20240229133653.0
024 7 _ |a 10.1016/j.zemedi.2021.03.006
|2 doi
024 7 _ |a pmid:34210537
|2 pmid
024 7 _ |a 0040-5973
|2 ISSN
024 7 _ |a 0939-3889
|2 ISSN
024 7 _ |a 1876-4436
|2 ISSN
037 _ _ |a DKFZ-2021-01500
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Höfel, Sebastian
|b 0
245 _ _ |a Suitability of superficial electron paramagnetic resonance dosimetry for in vivo measurement and verification of cumulative total doses during IMRT: A proof of principle.
260 _ _ |a Amsterdam
|c 2021
|b Elsevier, Urban & Fischer
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2021-11-01
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2021-11-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642584302_1941
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:E055# / Volume 31, Issue 4, November 2021, Pages 365-377
520 _ _ |a The present study investigates superficial in vivo dosimetry (IVD) by means of a previously proposed electron paramagnetic resonance (EPR) dosimetry system aiming at measuring and verifying total doses delivered by complex radiotherapy treatments. In view of novel regulatory requirements in Germany, differences between measured and planned total doses to the EPR dosimeters are analyzed and compared to reporting thresholds for significant occurrences.EPR dosimeters, each consisting of one lithium formate monohydrate (LFM) and one polycrystalline l-alanine (ALA) pellet, were attached to the surface of an anthropomorphic head phantom. Three head and neck treatments with total target doses ranging from 30 to 64Gy were fully delivered to the phantom by helical tomotherapy. During each treatment, eight EPR dosimeters were placed at distinct spots: (i) within or next to the planning target volume (PTV), (ii) near to organs at risk including the parotids and the lenses, (iii) at the thyroid lying out-of-field. EPR read out was always performed after all fractions were delivered. EPR results were compared to thermoluminescence dosimeter (TLD) measurements and to the planned total doses derived from the treatment planning system (TPS). Planned total doses to the EPR dosimeters ranged from about 2 to 64Gy.By taking uncertainties into account, the measured and planned doses were in good agreement. Exceptions occurred mainly at the thyroid (out-of-field) and lenses (extreme sparing). The maximum total dose difference between EPR results and corresponding planned doses was 1.3Gy occurring at the lenses. Remarkably, each LFM and ALA pellet placed within or next to the PTV provided dose values that were within ±4% of the planned dose. Dose deviations from planned dose values were comparable for EPR and TLD measurements.The results of this proof of principle study suggests that superficial EPR-IVD is applicable in a wide dose range and in various irradiation conditions - being a valuable tool for monitoring cumulative total doses delivered by complex IMRT treatments. EPR-IVD in combination with helical tomotherapy is suitable to reliably detect local dose deviations at superficial dosimeter spots in the order of current national reporting thresholds for significant occurrences (i.e. 10%/4Gy).
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
542 _ _ |i 2021-11-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
542 _ _ |i 2021-05-11
|2 Crossref
|u http://creativecommons.org/licenses/by-nc-nd/4.0/
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Alanine
|2 Other
650 _ 7 |a EPR dosimetry
|2 Other
650 _ 7 |a In vivo
|2 Other
650 _ 7 |a Intensity modulated radiotherapy
|2 Other
650 _ 7 |a Lithium formate
|2 Other
650 _ 7 |a Tomotherapy
|2 Other
700 1 _ |a Fix, Michael K
|b 1
700 1 _ |a Drescher, Malte
|b 2
700 1 _ |a Zwicker, Felix
|0 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c
|b 3
|e Last author
|u dkfz
773 1 8 |a 10.1016/j.zemedi.2021.03.006
|b Elsevier BV
|d 2021-11-01
|n 4
|p 365-377
|3 journal-article
|2 Crossref
|t Zeitschrift für Medizinische Physik
|v 31
|y 2021
|x 0939-3889
773 _ _ |a 10.1016/j.zemedi.2021.03.006
|g p. S0939388921000349
|0 PERI:(DE-600)2231492-1
|n 4
|p 365-377
|t Zeitschrift für medizinische Physik
|v 31
|y 2021
|x 0939-3889
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169693
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b Z MED PHYS : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Translationale Radioonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E055-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |1 International Atomic Energy Agency
|y 2016
|2 Crossref
|o International Atomic Energy Agency 2016
999 C 5 |a 10.1002/mp.12462
|9 -- missing cx lookup --
|1 Kry
|p e391 -
|2 Crossref
|t Med Phys
|v 44
|y 2017
999 C 5 |1 World Health Organization
|y 2008
|2 Crossref
|o World Health Organization 2008
999 C 5 |1 International Atomic Energy Agency
|y 2001
|2 Crossref
|o International Atomic Energy Agency 2001
999 C 5 |1 International Commission on Radiological Protection
|y 2000
|2 Crossref
|o International Commission on Radiological Protection 2000
999 C 5 |1 International Atomic Energy Agency
|y 2013
|2 Crossref
|o International Atomic Energy Agency 2013
999 C 5 |1 Van Dam
|y 2006
|2 Crossref
|o Van Dam 2006
999 C 5 |2 Crossref
|u Richtlinie 2013/59/Euratom vom 5. Dezember 2013 zur Festlegung grundlegender Sicherheitsnormen für den Schutz vor den Gefahren einer Exposition gegenüber ionisierender Strahlung und zur Aufhebung der Richtlinien 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom und 2003/122/Euratom, Amtsblatt der Europäischen Union L13/1 vom 17.01.2014.
999 C 5 |2 Crossref
|u Gesetz zum Schutz vor der schädlichen Wirkung ionisierender Strahlung vom 27. Juni 2017 (BGBl. 2017 I S. 1966).
999 C 5 |2 Crossref
|u Verordnung zum Schutz vor der schädlichen Wirkung ionisierender Strahlung vom 29. November 2018 (BGBl. 2018 I S. 2034, 2036).
999 C 5 |a 10.1007/s00411-013-0509-2
|9 -- missing cx lookup --
|1 Baffa
|p 233 -
|2 Crossref
|t Radiat Environ Biophys
|v 53
|y 2014
999 C 5 |1 Indovina
|y 1989
|2 Crossref
|o Indovina 1989
999 C 5 |a 10.1016/0969-8043(93)90042-9
|9 -- missing cx lookup --
|1 Kudynski
|p 903 -
|2 Crossref
|t Appl Radiat Isot
|v 44
|y 1993
999 C 5 |a 10.1016/S0969-8043(96)00171-6
|9 -- missing cx lookup --
|1 Kuntz
|p 1183 -
|2 Crossref
|t Appl Radiat Isot
|v 47
|y 1996
999 C 5 |a 10.1016/S0969-8043(96)00040-1
|9 -- missing cx lookup --
|1 Schaeken
|p 1177 -
|2 Crossref
|t Appl Radiat Isot
|v 47
|y 1996
999 C 5 |a 10.1016/j.radonc.2008.03.017
|9 -- missing cx lookup --
|1 Wagner
|p 140 -
|2 Crossref
|t Radiother Oncol
|v 88
|y 2008
999 C 5 |a 10.1093/rpd/ncu128
|9 -- missing cx lookup --
|1 Rech
|p 194 -
|2 Crossref
|t Radiat Prot Dosimetry
|v 159
|y 2014
999 C 5 |a 10.1088/1361-6560/aa6ee2
|9 -- missing cx lookup --
|1 Wagner
|p 5462 -
|2 Crossref
|t Phys Med Biol
|v 62
|y 2017
999 C 5 |a 10.1088/1361-6560/ab9414
|9 -- missing cx lookup --
|1 Höfel
|p 045005 -
|2 Crossref
|t Phys Med Biol
|v 66
|y 2021
999 C 5 |1 Netherlands Commission on Radiation Dosimetry
|y 2017
|2 Crossref
|o Netherlands Commission on Radiation Dosimetry 2017
999 C 5 |a 10.1118/1.3462971
|9 -- missing cx lookup --
|1 Langen
|p 4817 -
|2 Crossref
|t Med Phys
|v 37
|y 2010
999 C 5 |a 10.1016/S0168-9002(03)01368-8
|9 -- missing cx lookup --
|1 Agostinelli
|p 250 -
|2 Crossref
|t Nucl Instrum Methods Phys Res Sect A: Accel Spectrom Detect Assoc Equip
|v 506
|y 2003
999 C 5 |1 Sterpin
|y 2007
|2 Crossref
|o Sterpin 2007
999 C 5 |a 10.1088/0031-9155/53/8/011
|9 -- missing cx lookup --
|1 Sterpin
|p 2161 -
|2 Crossref
|t Phys Med Biol
|v 53
|y 2008
999 C 5 |2 Crossref
|u BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP and OIML, Evaluation of Measurement Data—Guide to the Expression of Uncertainty in Measurement JCGM 100:2008. https://www.bipm.org/utils/common/documents/jcgm/JCGM_100_2008_E.pdf.
999 C 5 |a 10.1016/j.zemedi.2013.10.008
|9 -- missing cx lookup --
|1 Schneider
|p 211 -
|2 Crossref
|t Zeit Med Phys
|v 24
|y 2014
999 C 5 |a 10.6028/jres.113.007
|1 Desrosiers
|9 -- missing cx lookup --
|2 Crossref
|t J Res Natl Inst Stand Technol
|v 113
|y 2008
999 C 5 |a 10.1088/0031-9155/53/17/014
|9 -- missing cx lookup --
|1 Gustafsson
|p 4667 -
|2 Crossref
|t Phys Med Biol
|v 53
|y 2008
999 C 5 |a 10.1016/j.radmeas.2011.03.014
|9 -- missing cx lookup --
|1 Waldeland
|p 945 -
|2 Crossref
|t Radiat Meas
|v 46
|y 2011
999 C 5 |a 10.1088/0031-9155/58/10/3259
|9 -- missing cx lookup --
|1 Anton
|p 3259 -
|2 Crossref
|t Phys Med Biol
|v 58
|y 2013
999 C 5 |a 10.1118/1.2757000
|9 -- missing cx lookup --
|1 Ramsey
|p 3286 -
|2 Crossref
|t Med Phys
|v 34
|y 2007
999 C 5 |a 10.1118/1.2952362
|9 -- missing cx lookup --
|1 Cheek
|p 3565 -
|2 Crossref
|t Med Phys
|v 35
|y 2008
999 C 5 |a 10.1016/j.ejmp.2012.04.004
|9 -- missing cx lookup --
|1 Avanzo
|p 304 -
|2 Crossref
|t Phys Med
|v 29
|y 2013
999 C 5 |1 Accuray Inc.
|y 2017
|2 Crossref
|o Accuray Inc. 2017
999 C 5 |1 Accuray Inc.
|y 2013
|2 Crossref
|o Accuray Inc. 2013
999 C 5 |a 10.4103/0973-1482.42255
|9 -- missing cx lookup --
|1 Kinhikar
|p 88 -
|2 Crossref
|t J Cancer Res Ther
|v 4
|y 2008
999 C 5 |a 10.1016/j.radonc.2009.07.005
|9 -- missing cx lookup --
|1 Reynders
|p 71 -
|2 Crossref
|t Radiother Oncol
|v 93
|y 2009
999 C 5 |a 10.1088/0031-9155/51/21/003
|9 -- missing cx lookup --
|1 Anton
|p 5419 -
|2 Crossref
|t Phys Med Biol
|v 51
|y 2006
999 C 5 |a 10.1088/0031-9155/56/5/010
|9 -- missing cx lookup --
|1 Wagner
|p 1373 -
|2 Crossref
|t Phys Med Biol
|v 56
|y 2011

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21